Interpace Biosciences announces 1-for-5 reverse stock split to support Nasdaq uplisting

INTERPACE BIOSCIENCES, INC.

1-for-5 reverse stock split effective 12:01 a.m. ET Aug 27, 2026; shares reduced from ~27.7M to ~5.5M.
Ticker temporarily changes to IDXGD for 20 trading days; new CUSIP 46062X402; par value unchanged at $0.01.
Split intended to meet Nasdaq minimum bid price requirement; company also needs $15M market value of unrestricted public shares.
Proportional adjustments to outstanding stock options, RSUs, and equity plan shares; fractional shares rounded up.
CEO Tom Burnell: split is key part of strategy to uplist to Nasdaq and attract broader investor base.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.